• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Omepra
    / Rafa


    Active Ingredient
    Omeprazole 20 mg, 40 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Capsules

    28 x 20 mg

    partial basket chart 13851 15340

    Capsules

    28 x 40 mg

    partial basket chart 13853 15342

    Related information


    Dosage

    See prescribing information for full details.


    Indications

    Acute duodenal/gastric ulcer, Helicobacter pylori associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: Long-term management treatment, maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux esophagitis in children from one year of age and older. Maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. Zollinger-Ellison Syndrome. Treatment and prevention of NSAID-associated duodenal and gastric ulcer or erosions in high risk patients.


    Contra-Indications

    Known hypersensitivity. Concomitant treatment with alazanavir.


    Special Precautions

    Pregnancy and lactation, pediatrics, hepatic disease. Malignancy should be excluded before commencement of treatment if gastric ulcer is suspected.
    See literature.


    Side Effects

    Headache, diarrhea, constipation, abdominal pain, nausea/vomiting, flatulence, and less common: Rash, urticaria, pruritus, malaise, dizziness, paresthesia, increased liver enzymes, somnolence, insomnia, and vertigo.


    Manufacturer
    Liconsa S.A.

    סרגל נגישות

    CLOSE